Micafungin sodium is an echinocandin antifungal that inhibits 1,3-β-D-glucan synthesis in Candida albicans[1]. Micafungin sodium is the sodium salt form of Micafungin (Cat. No. GC32244), which is used to treat a variety of fungal infections, including candidiasis and aspergillosis[2]. Micafungin can inhibit dengue virus infection by disrupting viral binding, entry, and stability[3]. Micafungin has the ability to stimulate phagocytes and promote immune responses, thereby inhibiting microbial infection[4]. Micafungin is a promising inhibitor of ubiquitin-conjugating enzyme E2M (UBE2M) and can inhibit cancer cell growth[5].
In vitro, treatment of erythrocytes with Micafungin (10-25µg/mL) for 48h significantly increased the percentage of hemolyzed and annexin V-bound cells and significantly reduced forward scatter[6].
In vivo, Micafungin (1mg/kg) was injected intraperitoneally to treat mice with mucormycosis and significantly improved the survival rate of mice, but it did not exert a synergistic effect when used in combination with Isavuconazonium sulphate[7]. Treatment of mice with doxorubicin-induced cardiotoxicity with Micafungin (10, 20mg/kg) improved cardiac function and inhibited oxidative stress, mitochondrial dysfunction, and cell death in a dose-dependent manner[8].
References:
[1] Vehreschild J J, Cornely O A. Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice[J]. Future Microbiology, 2006, 1(2): 161-170.
[2] Carver P L. Micafungin[J]. Annals of Pharmacotherapy, 2004, 38(10): 1707-1721.
[3] Chen Y C, Lu J W, Yeh C T, et al. Micafungin inhibits dengue virus infection through the disruption of virus binding, entry, and stability[J]. Pharmaceuticals, 2021, 14(4): 338.
[4] Fuchs B B, Li Y, Li D, et al. Micafungin elicits an immunomodulatory effect in Galleria mellonella and mice[J]. Mycopathologia, 2016, 181: 17-25.
[5] Mamun M A A, Liu S, Zhao L, et al. Micafungin: a promising inhibitor of UBE2M in cancer cell growth suppression[J]. European Journal of Medicinal Chemistry, 2023, 260: 115732.
[6] Peter T, Bissinger R, Signoretto E, et al. Micafungin-induced suicidal erythrocyte death[J]. Cellular Physiology and Biochemistry, 2016, 39(2): 584-595.
[7] Gebremariam T, Wiederhold N P, Alqarihi A, et al. Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis[J]. Journal of Antimicrobial Chemotherapy, 2016: dkw433.
[8] Lu L Q, Li M R, Huang L L, et al. Micafungin protects mouse heart against doxorubicin-induced oxidative injury via suppressing MALT1-dependent k48-linked ubiquitination of Nrf2[J]. Chemico-Biological Interactions, 2024, 400: 111179.
Micafungin sodium是一种棘白菌素类抗真菌药，能够抑制白色念珠菌中的1，3-β-D-葡聚糖合成[1]。Micafungin sodium是Micafungin（货号：GC32244）的钠盐形式，Micafungin能够用于治疗多种真菌感染，包括念珠菌病和曲霉病[2]。Micafungin能够通过破坏病毒结合、进入和稳定性来抑制登革热病毒感染[3]。Micafungin具有刺激吞噬细胞和促进免疫反应的能力，从而抑制微生物感染[4]。Micafungin是一种有前景的泛素结合酶E2M（UBE2M）抑制剂，可抑制癌细胞生长[5]。
在体外，Micafungin（10-25µg/mL）处理红细胞48h，显著增加了溶血和膜联蛋白V结合细胞的百分比，并显著减少前向散射[6]。
在体内，Micafungin（1mg/kg）通过腹腔注射治疗毛霉菌病小鼠，显著提高了小鼠的存活率，但与硫酸艾沙康唑（Isavuconazonium sulphate）联合使用并不能发挥协同作用[7]。Micafungin（10, 20mg/kg）治疗阿霉素诱导的心脏毒性模型小鼠，改善了心脏功能，以剂量依赖性方式抑制了氧化应激、线粒体功能障碍和细胞死亡[8]。